Firebrick Pharma Ltd Asset Resilience Ratio
Firebrick Pharma Ltd asset resilience ratio. Firebrick Pharma Ltd (FRE) has an Asset Resilience Ratio of 0.29% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Firebrick Pharma Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Firebrick Pharma Ltd (2021–2021)
Asset resilience ratio of Firebrick Pharma Ltd from 2021 to 2021. This chart shows how Firebrick Pharma Ltd's Asset Resilience Ratio has changed over time. Read Firebrick Pharma Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Firebrick Pharma Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Firebrick Pharma Ltd's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$5.35K | 0.29% |
| Total Liquid Assets | AU$5.35K | 0.29% |
Asset Resilience Insights
- Limited Liquidity: Firebrick Pharma Ltd maintains only 0.29% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Firebrick Pharma Ltd Industry Peers by Asset Resilience Ratio
Compare Firebrick Pharma Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.08% |
|
AstraZeneca PLC
NYSE:AZN |
Drug Manufacturers - General | 0.06% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019 |
Drug Manufacturers - General | 0.53% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 6.34% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436 |
Drug Manufacturers - General | 17.40% |
Firebrick Pharma Ltd Asset Resilience Ratio by Year (2021–2021)
Firebrick Pharma Ltd asset resilience ratio by year from 2021 to 2021. The table below shows the annual Asset Resilience Ratio data for Firebrick Pharma Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-06-30 | 2.41% | AU$283.24K ≈ $200.41K |
AU$11.77 Million ≈ $8.33 Million |
-- |
About Firebrick Pharma Ltd
Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.